Does Medicare cover Wegovy®? What to know about the GLP-1 Bridge program

Ask whether Medicare covers Wegovy® for weight loss, and until recently, the answer was always no. Beginning July 1, 2026, that’s changing. The new Medicare GLP-1 Bridge program will allow eligible Medicare beneficiaries to get certain weight-loss GLP-1 medications, including the Wegovy® injection and pill, for $50 a month.

The change is notable because Medicare has never been authorized to cover medications prescribed solely for weight loss under its standard Part D drug benefit. When Part D launched in 2006, weight loss medications were largely viewed as lifestyle treatments rather than medical therapies and were excluded from coverage.

Today, that view is shifting. Obesity is increasingly recognized as a chronic disease, and medications like Wegovy® have demonstrated benefits that extend beyond weight loss.

The Medicare GLP-1 Bridge program is an attempt to expand access while policymakers determine what long-term Medicare coverage for obesity treatment should look like. It’s important to understand, however, that Bridge is temporary, has specific eligibility requirements, and operates separately from traditional Medicare Part D coverage.

Here’s what to know about who qualifies, what’s covered, what you’ll pay, and how Bridge differs from ordinary Medicare drug coverage.

What is the Medicare GLP-1 Bridge program?

Medicare GLP-1 Bridge was created to give people who are medically in need of weight loss a lower, predictable price on GLP-1 weight-loss medications—while the government works out what permanent coverage should look like. It isn’t a new insurance plan, and you don’t sign up for it, though you need to have Part D coverage to qualify.

Coverage starts July 1, 2026, and is currently set to run through December 31, 2027. Because it operates on its own track, a single central processor handles the approvals, claims, and pharmacy payments, and your Part D plan neither manages it nor absorbs any of the cost.

The essentials:

• Covered medications are the Wegovy^® injection and pill, the Zepbound^® KwikPen^®, and the Foundayo^® pill.
• You pay $50 a month, and that price holds at every dose.
• It’s available in all 50 states plus U.S. territories.

When Bridge winds down, CMS plans to hand off to a longer demonstration called the BALANCE Model. 

Which forms of Wegovy^® does the Medicare GLP-1 Bridge program include?

The Medicare GLP-1 Bridge program includes the Wegovy® injection and pill for eligible beneficiaries. The $50 monthly copay is identical no matter which one you and your clinician choose. 

Both contain the same active ingredient, semaglutide, and work the same way in the body, by lowering appetite, slowing digestion, and regulating blood sugar. What separates them is how the medication is delivered and how often you take it. Each form starts low and steps up gradually over a few months, a process called titration that gives your body time to adjust. 

They also have different weight loss averages. In clinical trials, people taking the Wegovy® injection lost an average of about 18.7% of their starting weight when they reached the 7.2 mg dose. The Wegovy® pill was associated with an average weight loss of about 14% after 64 weeks of treatment. Individual results vary, and both medications work best when combined with lifestyle changes.

Wegovy^® injection

The injection is a once-weekly shot you give yourself under the skin, in the abdomen, thigh, or upper arm, using a single-dose prefilled pen. You can take it on any day at any time, with or without food, as long as you keep to the same day each week.

• How the dose increases: The dose is increased slowly, about every 4 weeks, until you reach the dose that gives you the best results with the fewest side effects.
• What is it approved for: The injection is FDA-approved for three uses: weight management, lowering the risk of heart disease, and treating MASH. 
• How does Medicare coverage work? If you qualify for the Bridge program, it’s covered at $50 a month when prescribed for weight loss. If your clinician prescribes it for heart-risk reduction or MASH, that prescription runs through your regular Medicare Part D plan rather than Bridge.

Wegovy^® pill

The pill is taken once a day in the morning with a small sip of water (no more than 4 ounces), and you need to wait 30 minutes before eating or drinking anything else.

• How the dose increases: Dosing starts at 1.5 mg once daily and will typically be increased every 30 days until you find the dose that gives you the best results with the fewest side effects. 
• What is it approved for: The pill is also approved for weight management, lowering the risk of heart disease, and treating MASH.
• How does Medicare coverage work? If you qualify for Bridge, the pill carries the same $50 monthly copay as the injection for weight loss.  If your clinician prescribes it for heart-risk reduction or MASH, that will be handled through your regular Medicare Part D plan rather than the Bridge. Our guide to the Wegovy® pill cost covers the daily option in more detail.

Who qualifies for Wegovy^® through the Medicare GLP-1 Bridge program?

Two boxes have to be checked. 

• First, the plan. You need to be enrolled in a Medicare Part D plan, either a standalone drug plan or a Medicare Advantage plan that bundles in drug coverage. 
• Second, you need to qualify to take the medication under Medicare Bridge rules.

It’s worth a quick refresher on how Medicare handles drugs. Original Medicare (Part A for hospital stays, Part B for outpatient care) doesn’t pay for take-home prescriptions at all. That coverage lives in Part D and in Medicare Advantage plans that include it. 

A Medigap policy can soften your other out-of-pocket costs, but it adds no drug coverage of its own. So the Bridge is anchored to Part D.

On the clinical side, the program has certain BMI and comorbidity rules for who qualifies. A high enough BMI clears you on its own; a lower BMI works if you also have another qualifying condition. This table lays out what to expect:

BMI (when you first started GLP-1 medication)	What else has to be true
35 or higher	Nothing else needed; the BMI alone qualifies you.
30 or higher	Plus one of these: heart failure with preserved ejection fraction, high blood pressure that stays above 140/90 despite two medications, or chronic kidney disease at stage 3a or beyond.
27 or higher	Plus one of these: pre-diabetes (by ADA guidelines), a prior heart attack, a prior stroke, or symptomatic peripheral artery disease.

The qualifications refer to your current situation or your health profile when you first started GLP-1 medication therapy. For example, someone who began Wegovy^® in early 2025 at a BMI of 35 and has since brought it down to 33 would still qualify for coverage and continued treatment. That’s also true if you started a GLP-1 before you ever joined Medicare.

A few plan types are left out. If you’re in a private fee-for-service plan, a PACE program, or certain other arrangements, you generally can’t use the Bridge unless you also carry a standalone Part D plan.

What the Medicare GLP-1 Bridge doesn’t cover

The Medicare GLP-1 Bridge program just covers weight management. Here are a few important points to keep in mind:

• If you already get a GLP-1 through Part D for a covered condition, such as heart-risk reduction or MASH, it stays on your plan. You can’t move that same prescription onto the Bridge.
• The $50 copay never counts toward your Part D deductible or your $2,100 out-of-pocket maximum.
• Extra Help doesn’t apply. If you’re used to $5 or $10 copays through that subsidy, the $50 will feel like a real line item.

Any GLP-1 prescription that qualifies for Part D isn’t covered by Bridge.

Does Medicare cover Wegovy^® for heart disease?

Yes, for certain people. In March 2024, the FDA approved Wegovy^® to cut the risk of major cardiovascular events (heart attack, stroke, and cardiovascular death) in people with heart disease and a BMI of 27 or higher. 

Does Medicare cover Wegovy^® for MASH?

It can. MASH (metabolic dysfunction-associated steatohepatitis) is a serious fatty liver disease that scars the liver as it advances. In August 2025, the FDA gave accelerated approval to the Wegovy^® injection (semaglutide 2.4 mg) for adults with noncirrhotic MASH and moderate-to-advanced scarring, the first GLP-1 cleared for the condition.

Like the heart-disease route, MASH coverage flows through regular Part D rather than Bridge, and it comes with prior authorization. Expect your doctor to submit records confirming the diagnosis and that you meet the treatment criteria, which can mean liver function tests and fibrosis staging.

Does Medicare GLP-1 Bridge cover every GLP-1?

No. It names a specific set of weight-management products: Wegovy^® (both forms), the Zepbound^® KwikPen, and Foundayo^®. Other GLP-1s may still be covered through standard Part D when they treat something Medicare recognizes, like diabetes. Here’s the wider picture:

Active ingredient	What it’s FDA-approved to treat	Where Medicare coverage stands*
Semaglutide	Wegovy® injection & pill: Weight management; heart-risk reduction; MASH Ozempic® & Ozempic pill® : Type-2 diabetes	Wegovy: Both forms are covered through Bridge for weight loss. They go through Part D for heart disease or MASH. Ozempic: May be covered by Part D for diabetes.
Orforglipron	Foundayo®: Weight management	Covered through the Bridge for weight loss if you qualify. No other FDA-approved use yet, so no standard Part D route.
Tirzepatide	Zepbound® : Weight management; OSA Mounjaro®: Diabetes	Zepbound: Only the KwikPen runs through the Bridge; the single-dose pen may be covered by Part D for OSA. The single-dose vials aren’t covered and are cash-pay only through Lilly Direct.  Mounjaro: May be covered by Part D for diabetes.
Liraglutide	Saxenda®: Weight management Victoza® Type 2 diabetes; heart risk Generic liraglutide: Weight management; Type 2 diabetes; heart risk	Saxenda®: Not on the Bridge list, and not covered for weight loss. Victoza®: May be covered by Part D for diabetes or heart disease. Generic liraglutide: Not on the Bridge list, and not covered for weight loss. May be covered by Part D for diabetes or heart disease.

*What your plan actually covers depends on its formulary, prior authorization rules, and any step therapy requirements. Check with your plan before you count on anything.

Read more: Does Medicare cover weight loss drugs?

Medicare Bridge and Wegovy: What changes on July 1, 2026?

That date is when the program begins. Until then, the old rules govern: no weight-loss coverage, and Wegovy is only covered by Medicare when it treats a condition like heart disease or MASH. From July 1 on, three things are true:

• Eligible Part D members can fill the Wegovy^® injection or pill for weight loss at $50 a month.
• Your $50 is far below the real cost. Manufacturers supply the drug to the program at a net $245 per monthly fill, which is what makes the low copay possible.
• Your prescriber doesn’t have to be a Medicare-enrolled provider to write the prescription or request Bridge approval.

Keep one thing in perspective: the underlying law hasn’t changed. Congress hasn’t opened Medicare to weight-loss drugs in general. This is a time-limited experiment, and what happens after December 2027 is still unwritten.

What if you don’t qualify, or Bridge ends?

You still have options. Novo Nordisk sells Wegovy^® to cash payers through NovoCare^® Pharmacy. While the price isn’t $50 a month, it’s cheaper than the retail price of about $1,350.

Wegovy injection 

• $199: 0.25 mg and 0.5 mg
• $349:1 mg, 1.7 mg, and 2.4 mg
• $399: 7.2 mg

Wegovy pill

• $149: 1.5 mg;
• $149–$199: 4 mg*
• $299: 9 mg and 25 mg

Our breakdown of Wegovy^® cost without insurance runs through the options.

*$149 pricing for 4 mg available until August 31, 2026, then $199/month.

Frequently asked questions about Medicare coverage for Wegovy^®

Getting Wegovy^® through Medicare typically starts with a conversation with your healthcare provider. They can determine whether ^® is appropriate for your situation and help you understand whether you meet any coverage requirements. From there, you’ll need to check your specific Medicare plan’s formulary, coverage rules, and potential out-of-pocket costs. Because coverage can vary between plans, it’s worth reviewing your benefits carefully before filling a prescription.

How do I actually get Wegovy^® through Medicare?

Once the Bridge opens on July 1, 2026, the path runs through your prescriber. If you’re in an eligible Part D plan and meet the criteria, they submit a prior authorization to the Bridge’s processor. After it clears, you pick up the Wegovy^® injection or pill at the pharmacy for $50. If the prescription is for heart disease or MASH instead, it goes through your regular Part D plan, not the Bridge.

What will Wegovy^® cost me on Medicare?

Through the Medicare GLP-1 Bridge program, $50 a month for any dose and for either form. Just remember that $50 doesn’t build toward your deductible or out-of-pocket cap. If you’re covered through Part D for heart disease or MASH instead, your cost follows your plan’s drug tier and benefit phase.

Which diagnoses open up Wegovy^® coverage?

For Bridge, it’s weight management paired with a qualifying BMI, sometimes alongside a condition like pre-diabetes, a cardiac history, or kidney disease. Outside of Bridge, standard Part D may cover Wegovy^® for heart-risk reduction or MASH. 

Does Medicare cover Zepbound?

Starting July 1, 2026, the Medicare GLP-1 Bridge program will also cover the Zepbound^® KwikPen for weight loss at $50 a month. Apart from that, Zepbound^® can be covered by Part D for obstructive sleep apnea (OSA). Read more about Zepbound coverage through the Medicare GLP-1 Bridge program.

The bottom line: Medicare GLP-1 Bridge will cover Wegovy® for qualified people

For years, Medicare beneficiaries who wanted Wegovy® for weight loss would have to pay cash prices. Medicare drug coverage doesn’t pay for medications prescribed solely for obesity, leaving many people to cover the full cost themselves.

The Medicare GLP-1 Bridge program changes that, at least temporarily. Starting July 1, 2026, eligible beneficiaries with Medicare Part D can access the Wegovy® injection or pill for $50 a month, regardless of dose. The program also covers the Zepbound® KwikPen and Foundayo®, giving people on Medicare more affordable access to medications that were previously out of reach for many.

The details matter. Bridge coverage has specific BMI and health-condition requirements; the $50 copay doesn’t count toward your Part D spending limits, and the program is currently scheduled to end in December 2027. It’s also separate from ordinary Medicare Part D coverage, which may still cover Wegovy® for certain conditions.

If you’re interested in Wegovy®, the best first step is to talk with your healthcare provider. They can help determine whether you meet the Bridge eligibility requirements, whether another Medicare coverage pathway may apply, and which treatment option makes the most sense for your health goals and medical history.

This article is for general education and isn’t medical or insurance advice. Medicare rules, drug approvals, and prices change often. Confirm the current details with CMS, Medicare.gov, your plan, and your healthcare provider before deciding anything.